Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › rituximab

rituximab

31 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of rituximab

424 trials tracked of rituximab: 83 in phase 3 or 4 and 34 with published results. The most-cited published study has 955 citations.

424Trials tracked
83Phase 3 & 4
0Recruiting
34With published results
Phase distribution
Phase 4 8 Phase 3 75 Phase 2 304 Phase 1 12 Other / NA 25
  1. Phase 3 A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Completed · 955 cited
  2. Phase 3 A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Completed · 612 cited
  3. Phase 3 MEmbranous Nephropathy Trial Of Rituximab Completed · 589 cited
  4. Phase 3 A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) Completed · 490 cited
  5. Phase 3 Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Completed · 421 cited
  6. Phase 3 Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) Completed · 417 cited
Show 44 more trials
  1. Phase 3 Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma Completed · 360 cited
  2. Phase 3 Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Completed · 348 cited
  3. Phase 3 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed · 341 cited
  4. Phase 3 A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Completed · 300 cited
  5. Phase 3 Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma Completed · 268 cited
  6. Phase 3 A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed · 258 cited
  7. Phase 3 Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) Completed · 247 cited
  8. Phase 3 Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma Completed · 226 cited
  9. Phase 3 A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma Completed · 210 cited
  10. Phase 3 A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis Completed · 189 cited
  11. Phase 3 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed · 188 cited
  12. Phase 3 A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a Completed · 150 cited
  13. Phase 3 Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) Completed · 136 cited
  14. Phase 3 Rituximab Vasculitis Maintenance Study Completed · 115 cited
  15. Phase 3 A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) Completed · 112 cited
  16. Phase 3 A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE Completed · 111 cited
  17. Phase 3 GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) Completed · 82 cited
  18. Phase 3 To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan Completed · 75 cited
  19. Phase 3 A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab Completed · 65 cited
  20. Phase 3 To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma Completed · 63 cited
  21. Phase 3 PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis Completed · 52 cited
  22. Phase 3 A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) Completed · 32 cited
  23. Phase 3 A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma Completed · 25 cited
  24. Phase 3 Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab Completed · 19 cited
  25. Phase 3 MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma Completed · 16 cited
  26. Phase 3 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed · 15 cited
  27. Phase 3 A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma Completed · 8 cited
  28. Phase 4 Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes Completed · 6 cited
  29. Phase 4 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Completed
  30. Phase 4 Rituximab (RTX) Therapy in Patients With Active TAO Completed
  31. Phase 4 Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients Completed
  32. Phase 4 A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis Completed
  33. Phase 4 Desensitization in Kidney Transplantation Completed
  34. Phase 4 An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease Completed
  35. Phase 4 A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies. Completed
  36. Phase 3 Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients Completed
  37. Phase 3 A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma Completed
  38. Phase 3 A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL) Completed
  39. Phase 3 Safety of Switching From Rituximab to Ocrelizumab in MS Patients Completed
  40. Phase 3 A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Completed
  41. Phase 3 Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients Completed
  42. Phase 3 MabionCD20 Compared to MabThera in Lymphoma Patients Completed
  43. Phase 3 Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A Completed
  44. Phase 3 A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation Completed

Showing the 50 most-cited and recently-updated of 424 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Mechanism-based strategies including CAR-T and bispecific engagers offer options for rituximab-resistant primary membranous nephropathy
Allergy & Immunology Sys. Review
Mechanism-based strategies including CAR-T and bispecific engagers offer options for rituximab-resistant primary membranous nephropathy New Strategies Target Treatment Resistance in Membranous Nephropathy
This systematic review examines the multifactorial mechanisms of rituximab resistance in patients with primary membranous nephropathy. It id…
Researchers identify new ways to treat primary membranous nephropathy when standard rituximab treatments do not work.
Frontiers Jun 11, 2026
Biologic and targeted synthetic DMARDs show reassuring malignancy safety in inflammatory arthritides, but non-melanoma skin cancer risk rises with TNF inhibitors
Allergy & Immunology Sys. Review
Biologic and targeted synthetic DMARDs show reassuring malignancy safety in inflammatory arthritides, but non-melanoma skin cancer risk rises with TNF inhibitors Biologics for arthritis: Cancer risk appears low overall
This narrative review of biologic and targeted synthetic DMARDs in immune-mediated inflammatory arthritides finds most therapies have reassu…
Most biologic arthritis drugs don't raise overall cancer risk, but skin cancer risk may be higher with some.
Frontiers Jun 4, 2026
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
Oncology Sys. Review
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma Attenuated R-THP-COP regimen shows promise for elderly diffuse large B-cell lymphoma
This case report describes an 85-year-old female patient with diffuse large B-cell lymphoma treated with an attenuated R-THP-COP regimen. Th…
An 85-year-old woman achieved complete radiological response and remained symptom-free for three years on an attenuated chemotherapy regimen…
Frontiers Jun 2, 2026
Immunotherapies beyond rituximab show high response rates in diffuse large B-cell lymphoma
Allergy & Immunology Sys. Review
Immunotherapies beyond rituximab show high response rates in diffuse large B-cell lymphoma New immunotherapy options offer high response rates for Diffuse Large B-Cell Lymphoma patients
This narrative review surveys immunotherapy options for diffuse large B-cell lymphoma beyond rituximab, including bispecific antibodies, CAR…
New immunotherapy treatments show high response rates for Diffuse Large B-Cell Lymphoma, offering hope beyond the standard 60% success rate …
Frontiers May 29, 2026
Rituximab rechallenge caused severe hypersensitivity reaction in a patient with membranous nephropathy
Drug Pipeline Sys. Review
Rituximab rechallenge caused severe hypersensitivity reaction in a patient with membranous nephropathy A third Rituximab dose caused severe shock in a man with kidney disease
This case report describes a 52-year-old male with biopsy-proven primary membranous nephropathy who received a third 1 g infusion of rituxim…
A man with kidney disease developed life-threatening shock after a third Rituximab infusion, highlighting the need for careful monitoring an…
Frontiers May 29, 2026
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Infectious Disease Meta-analysis
Meta-analysis of double-expressor lymphoma prognoses and novel therapies Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Frontiers May 22, 2026
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
Oncology RCT
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
JAMA May 19, 2026
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Oncology RCT
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
May 16, 2026
Case report of obinutuzumab-induced acute bicytopenia in autoimmune disease
Allergy & Immunology Sys. Review
Case report of obinutuzumab-induced acute bicytopenia in autoimmune disease A Common Lupus Drug Caused a Man's Platelets to Nearly Disappear
This is a case report and literature review describing a 55-year-old male with ANCA-associated glomerulonephritis who developed acute thromb…
A man with autoimmune kidney disease lost nearly all his platelets after a common cancer drug, and doctors say the warning signs were hiding…
Frontiers May 5, 2026
Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Oncology RCT
Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs.
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…
Apr 28, 2026
Narrative review links myasthenia gravis and autoimmune encephalitis risk
Neurology Sys. Review
Narrative review links myasthenia gravis and autoimmune encephalitis risk MG and Brain Inflammation Linked in New Review
This narrative review examines the association between myasthenia gravis and autoimmune encephalitis.
This review reveals that myasthenia gravis is often linked to brain inflammation — and that may change how doctors treat tough cases.
Frontiers Apr 24, 2026
Sequential efgartigimod and rituximab induced improvement in three patients with refractory autoimmune encephalitis
Psychiatry Cohort
Sequential efgartigimod and rituximab induced improvement in three patients with refractory autoimmune encephalitis Sequential efgartigimod and rituximab showed improvement in three patients with autoimmune encephalitis
This case series describes three patients with refractory autoimmune encephalitis treated with sequential efgartigimod and rituximab.
Three patients with difficult autoimmune encephalitis improved after sequential treatment, suggesting a potential new option for those who d…
Frontiers Apr 24, 2026

All rituximab Articles